Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Prevention of Acute Graft-Versus-Host Disease in Human/Mouse Xenogeneic SCID Mouse Model by Humanized Anti-CD74 Monoclonal Antibody, Milatuzumab

Xiaochuan Chen, Ph.D, Chien-Hsing Chang, Ph.D, Rhona Stein, Ph.D, Thomas M Cardillo, Ph.D, David V. Gold, Ph.D., David M Goldenberg, ScD, MD

Blood (2012) 120 (21): 4105.

https://doi.org/10.1182/blood.V120.21.4105.4105

Published: 2012

Journal Articles

Preclinical studies on targeted delivery of multiple IFNα2b to HLA-DR in diverse hematologic cancers

Edmund A. Rossi, Diane L. Rossi, Thomas M. Cardillo, Rhona Stein, David M. Goldenberg, Chien-Hsing Chang

Blood (2011) 118 (7): 1877–1884.

https://doi.org/10.1182/blood-2011-03-343145

Published: 2011

Includes: Supplemental data

Journal Articles

Milatuzumab Improves Efficacy of Current Treatments for B-Cell Malignancies.

Rhona Stein, Ph.D., Susan Chen, Francisco J. Hernandez-Ilizaliturri, M.D., Myron S. Czuczman, MD, David M. Goldenberg, Sc.D., M.D.

Blood (2010) 116 (21): 2837.

https://doi.org/10.1182/blood.V116.21.2837.2837

Published: 2010

Journal Articles

CD74 Expression by AML Cell Lines and Bone Marrow Specimens, and Augmented In Vitro Cytotoxicity of Anti-CD74 Antibody After Interferon-Gamma (IFN-γ) Treatment

Abhinav B. Chandra, MD, MSc, Jack Burton, Rhona Stein, Susan Chen, Nidhi Mishra, MBBS, MD, Taral Shah, Nneamaka N Enwemnwa, MD, David Goldenberg

Blood (2010) 116 (21): 2888.

https://doi.org/10.1182/blood.V116.21.2888.2888

Published: 2010

Journal Articles

Depletion of Blood Antigen-Presenting Cells by IMMU-114: Therapeutic Potential Against Graft-Versus-Host Disease

Xiaochuan Chen, Chien-Hsing Chang, Rhona Stein, David Goldenberg

Blood (2010) 116 (21): 2544.

https://doi.org/10.1182/blood.V116.21.2544.2544

Published: 2010

Journal Articles

Therapy of B-cell malignancies by anti–HLA-DR humanized monoclonal antibody, IMMU-114, is mediated through hyperactivation of ERK and JNK MAP kinase signaling pathways

Rhona Stein, Pankaj Gupta, Xiaochuan Chen, Thomas M. Cardillo, Richard R. Furman, Susan Chen, Chien-Hsing Chang, David M. Goldenberg

Blood (2010) 115 (25): 5180–5190.

https://doi.org/10.1182/blood-2009-06-228288

Published: 2010

Includes: Supplemental data

Journal Articles

Differential Effects of Milatuzumab On Human Antigen-Presenting Cells in Comparison to Malignant B Cells.

Xiaochuan Chen, Ph.D., Rhona Stein, PhD, Chien-Hsing Chang, PhD, David M. Goldenberg, ScD, MD

Blood (2009) 114 (22): 2744.

https://doi.org/10.1182/blood.V114.22.2744.2744

Published: 2009

Journal Articles

Therapy of B-Cell Malignancies by Anti-HLA-DR Humanized Monoclonal Antibody, IMMU-114, Is Mediated through Hyperactivation of ERK and JNK MAP Kinase Signaling Pathways.

Pankaj Gupta, Ph.D, Rhona Stein, PhD, Thomas M Cardillo, PhD, Richard R Furman, Susan Chen, Chien-Hsing Chang, PhD, David M. Goldenberg, ScD, MD

Blood (2009) 114 (22): 3738.

https://doi.org/10.1182/blood.V114.22.3738.3738

Published: 2009

Journal Articles

CD200 Is Preferentially Expressed in CD138 dim Multiple Myeloma Cells: Implications for a Myeloma Stem Cell Subpopulation with Potential Immune-Resistance.

Xiaochuan Chen, Ph.D., Rhona Stein, PhD, David M. Goldenberg, ScD, MD

Blood (2009) 114 (22): 4877.

https://doi.org/10.1182/blood.V114.22.4877.4877

Published: 2009

Journal Articles

CD20-targeted tetrameric interferon-α, a novel and potent immunocytokine for the therapy of B-cell lymphomas

Edmund A. Rossi, David M. Goldenberg, Thomas M. Cardillo, Rhona Stein, Chien-Hsing Chang

Blood (2009) 114 (18): 3864–3871.

https://doi.org/10.1182/blood-2009-06-228890

Published: 2009

Includes: Supplemental data

Journal Articles

Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20/CD22 antibodies in lymphoma

Edmund A. Rossi, David M. Goldenberg, Thomas M. Cardillo, Rhona Stein, Chien-Hsing Chang

Blood (2009) 113 (24): 6161–6171.

https://doi.org/10.1182/blood-2008-10-187138

Published: 2009

Includes: Supplemental data

Journal Articles

Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody

David M. Goldenberg, Edmund A. Rossi, Rhona Stein, Thomas M. Cardillo, Myron S. Czuczman, Francisco J. Hernandez-Ilizaliturri, Hans J. Hansen, Chien-Hsing Chang

Blood (2009) 113 (5): 1062–1070.

https://doi.org/10.1182/blood-2008-07-168146

Published: 2009

Includes: Supplemental data

Journal Articles

Bispecific Anti-CD20/Anti-CD22 Antibodies with Potent Lymphoma Cytotoxicity.

Edmund A Rossi, PhD, Chien-Hsing Chang, PhD, Thomas M Cardillo, PhD, Rhona Stein, PhD, Diana Pilas, Diane L Nordstrom, John Kopinski, David M. Goldenberg, ScD, MD

Blood (2008) 112 (11): 1591.

https://doi.org/10.1182/blood.V112.11.1591.1591

Published: 2008

Journal Articles

Improved Therapy of Multiple Myeloma by Combining Milatuzumab (Anti-CD74 Humanized mAb) and Bortezomib: In Vitro and In Vivo Results.

Rhona Stein, PhD, David M. Goldenberg, ScD, MD

Blood (2007) 110 (11): 1176.

https://doi.org/10.1182/blood.V110.11.1176.1176

Published: 2007

Journal Articles

Recombinant Protein A Activity in SCID Mouse Models of Human B Cell Tumors.

Andrew Cooper, MMSc, PhD, Rhona Stein, PhD, Katherine Hall, Richard Boismenu, PhD, Susan Chen, BS, James Rusche, PhD

Blood (2006) 108 (11): 4757.

https://doi.org/10.1182/blood.V108.11.4757.4757

Published: 2006

Journal Articles

Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab

Rhona Stein, Zhengxing Qu, Susan Chen, David Solis, Hans J. Hansen, David M. Goldenberg

Blood (2006) 108 (8): 2736–2744.

https://doi.org/10.1182/blood-2006-04-017921

Published: 2006

Journal Articles

Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies

Rhona Stein, Zhengxing Qu, Thomas M. Cardillo, Susan Chen, Adriane Rosario, Ivan D. Horak, Hans J. Hansen, David M. Goldenberg

Blood (2004) 104 (12): 3705–3711.

https://doi.org/10.1182/blood-2004-03-0890

Published: 2004

Journal Articles

In Vitro and In Vivo Targeting and Therapy of an Antibody-Drug Conjugate (IMMU-110) in B-Cell Malignancies.

Puja Sapra, PhD, Rhona Stein, PhD, Jennifer Pickett, PhD, Serengulam V. Govindan, PhD, Thomas M. Cardillo, PhD, Christopher Damoci, BS, Agatha Sheerin, BS, Hans J. Hansen, PhD, Ivan D. Horak, MD, Gary L. Griffiths, PhD, David M. Goldenberg, ScD, MD

Blood (2004) 104 (11): 3287.

https://doi.org/10.1182/blood.V104.11.3287.3287

Published: 2004

NARROW

Prevention of Acute Graft-Versus-Host Disease in Human/Mouse Xenogeneic SCID Mouse Model by Humanized Anti-CD74 Monoclonal Antibody, Milatuzumab

Preclinical studies on targeted delivery of multiple IFNα2b to HLA-DR in diverse hematologic cancers

Milatuzumab Improves Efficacy of Current Treatments for B-Cell Malignancies.

CD74 Expression by AML Cell Lines and Bone Marrow Specimens, and Augmented In Vitro Cytotoxicity of Anti-CD74 Antibody After Interferon-Gamma (IFN-γ) Treatment

Depletion of Blood Antigen-Presenting Cells by IMMU-114: Therapeutic Potential Against Graft-Versus-Host Disease

Therapy of B-cell malignancies by anti–HLA-DR humanized monoclonal antibody, IMMU-114, is mediated through hyperactivation of ERK and JNK MAP kinase signaling pathways

Differential Effects of Milatuzumab On Human Antigen-Presenting Cells in Comparison to Malignant B Cells.

Therapy of B-Cell Malignancies by Anti-HLA-DR Humanized Monoclonal Antibody, IMMU-114, Is Mediated through Hyperactivation of ERK and JNK MAP Kinase Signaling Pathways.

CD200 Is Preferentially Expressed in CD138 dim Multiple Myeloma Cells: Implications for a Myeloma Stem Cell Subpopulation with Potential Immune-Resistance.

CD20-targeted tetrameric interferon-α, a novel and potent immunocytokine for the therapy of B-cell lymphomas

Hexavalent bispecific antibodies represent a new class of anticancer therapeutics: 1. Properties of anti-CD20/CD22 antibodies in lymphoma

Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody

Bispecific Anti-CD20/Anti-CD22 Antibodies with Potent Lymphoma Cytotoxicity.

Improved Therapy of Multiple Myeloma by Combining Milatuzumab (Anti-CD74 Humanized mAb) and Bortezomib: In Vitro and In Vivo Results.

Recombinant Protein A Activity in SCID Mouse Models of Human B Cell Tumors.

Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab

Antiproliferative activity of a humanized anti-CD74 monoclonal antibody, hLL1, on B-cell malignancies

In Vitro and In Vivo Targeting and Therapy of an Antibody-Drug Conjugate (IMMU-110) in B-Cell Malignancies.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only